717
Views & Citations10
Likes & Shares
In this presentation, we would like to concentrate on the following
aspects in relation to COVID-19. First of all, we think that the period since
the appearance of COVID-19 as a pandemic issue is still relatively short.
However, thousands of articles have been published. We were looking for
research articles investigating the aspects of genetic polymorphism and viral
load, but there is some sort of disturbance among researchers. We think that
genetic polymorphism and viral load are crucial determinants in therapeutic
responses against COVID-19. In-depth investigation of these two variables makes
the core of developing therapeutic options. We have previous experience in HCV.
In HCV, both viral load and genetic polymorphism are important features in
treatment options. Viral load helps in identifying degree level of infecting
potentiality. For example, two phenomena can be explained, the first phenomenon
is why COVID-19 has various degrees of infectious potential. As an illustrating
example, if the viral load is relatively low, then the infectious ability is
limited, and if the viral load is high, then any one exposed can be infected.
The second phenomenon is when the best time to initiate treatment against
COVID-19. If treatment is initiated when viral load is limited, treatment is
almost successful. Regarding genetic polymorphism, initial information about
COVID-19 was related to respiratory system, particularly the lungs.
Polymorphisms in ACE2 is thought to play a role in the infectious ability of
COVID-19. The expression of ACE2 receptors was reported in various tissues
including liver, and kidneys. Accordingly, we can explain the impacts of
COVID-19 on other systems. Finally, we got the idea why diabetic patients and
heart patients are more likely to have adverse effects by COVID-19. We think
this is due to synergistic effects of having other viruses such as HPV and CMV
in case of diabetes as we found experimentally. In heart cases, we also have
previously found that Chlamydia pneumonia to exist in about 50% of patients
with heart diseases. Synergism of the various pathogens in COVID-19 is worthy
to be more investigated.
Keywords: COVID-19, Genetic polymorphism, Viral load,
Infectious potential, Polymorphism
QUICK LINKS
- SUBMIT MANUSCRIPT
- RECOMMEND THE JOURNAL
-
SUBSCRIBE FOR ALERTS
RELATED JOURNALS
- Archive of Obstetrics Gynecology and Reproductive Medicine (ISSN:2640-2297)
- Journal of Oral Health and Dentistry (ISSN: 2638-499X)
- Chemotherapy Research Journal (ISSN:2642-0236)
- BioMed Research Journal (ISSN:2578-8892)
- Journal of Rheumatology Research (ISSN:2641-6999)
- Advance Research on Alzheimers and Parkinsons Disease
- International Journal of Diabetes (ISSN: 2644-3031)